论文部分内容阅读
为了验证汉丹肝乐治疗慢性活动性肝炎肝纤维化的临床效果，将６６例慢性乙型活动性肝炎肝纤维化患者随机分为两组，在相同基础治疗下，治疗组３６例加服汉丹肝乐。结果显示，汉丹肝乐在改善症状体征，降低血清丙氨酸转移酶（ＡＬＴ），纠正白蛋白与球蛋白比例（Ａ／Ｇ），降低血清透明质酸（ＨＡ）、层粘蛋白（ＬＮ）、Ⅲ型前胶原（ＰＣⅢ）等方面有良好效果，整个疗程中未见任何不良反应。它对乙型肝炎病毒标记物（ＨＢｖＭｓ）阴转率低。认为汉丹肝乐有希望成为抗慢性乙型活动性肝炎肝纤维化的良好药物
In order to verify the clinical effect of Handan Gan Le on treating chronic active hepatitis with hepatic fibrosis, 66 patients with chronic hepatitis B who had liver fibrosis were randomly divided into two groups. Under the same basic treatment, 36 patients in the treatment group were treated with Chinese medicine. Dangan Le. The results showed that Handanganle improves symptoms and signs, reduces serum alanine transferase (ALT), corrects the ratio of albumin to globulin (A/G), and decreases serum hyaluronic acid (HA) and laminin (LN). ), Type III procollagen (PCIII) and other aspects have good results, no adverse reactions throughout the course of treatment. Its negative conversion rate for hepatitis B virus markers (HBvMs) is low. Recognizes Handan Ganille as a good drug for liver fibrosis against chronic active hepatitis B